Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioTTT001 in malignant solid tumors
NCT06215846Phase 1Enrolling by invitation
- Sponsor
- Beijing Bio-Targeting Therapeutics
- Start
- May 2024
- Primary completion
- May 2026
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BioTTT001 in solid tumor, sponsored by Beijing Bio-Targeting Therapeutics. Primary endpoints: Adverse Events at 28 days and Maximum Tolerated Dose at 28 days. Started May 2024; status: enrolling by invitation.
02
Drugs
BioTTT001
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06215846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06215846.